Literature DB >> 17005842

In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.

Cornelius J Clancy1, Benjamin Staley, M Hong Nguyen.   

Abstract

We determined MICs for 28 Candida isolates recovered from patients who developed breakthrough candidemia while receiving fluconazole. MICs correlated with daily and cumulative doses of fluconazole. Patients receiving > or =2,000 mg cumulatively or >200 mg daily were more likely to be infected with isolates that were not fluconazole susceptible.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17005842      PMCID： PMC1610054          DOI： 10.1128/AAC.00741-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

2.  Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis.

Authors:  Andrew F Shorr; Kevin Chung; William L Jackson; Paige E Waterman; Marin H Kollef
Journal:  Crit Care Med       Date:  2005-09       Impact factor: 7.598

3.  Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.

Authors:  A Safdar; F van Rhee; J P Henslee-Downey; S Singhal; J Mehta
Journal:  Bone Marrow Transplant       Date:  2001-11       Impact factor: 5.483

4.  Risk factors for breakthrough candidemia.

Authors:  M Nucci; A L Colombo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-19       Impact factor: 3.267

5.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

Authors:  K A Marr; K Seidel; T C White; R A Bowden
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

6.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

7.  Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.

Authors:  J R Wingard; W G Merz; M G Rinaldi; C B Miller; J E Karp; R Saral
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit.

Authors:  Sandra M Swoboda; William G Merz; Pamela A Lipsetta
Journal:  Surg Infect (Larchmt)       Date:  2003       Impact factor: 2.150

9.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; R J Hollis; C Rice; S Tendolkar; D J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

10.  Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.

Authors:  Yoshinari Myoken; Tai-ichi Kyo; Megumu Fujihara; Tatsumi Sugata; Yuzuru Mikami
Journal:  Haematologica       Date:  2004-03       Impact factor: 9.941
View more
  13 in total

1.  Population pharmacokinetics of fluconazole in young infants.

Authors:  K C Wade; D Wu; D A Kaufman; R M Ward; D K Benjamin; J E Sullivan; N Ramey; B Jayaraman; K Hoppu; P C Adamson; M R Gastonguay; J S Barrett
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

2.  Hyporientalin A, an anti-Candida peptaibol from a marine Trichoderma orientale.

Authors:  Ines Touati; Nicolas Ruiz; Olivier Thomas; Irina S Druzhinina; Lea Atanasova; Olfa Tabbene; Salem Elkahoui; Roudaina Benzekri; Lamjed Bouslama; Yves François Pouchus; Ferid Limam
Journal:  World J Microbiol Biotechnol       Date:  2018-06-19       Impact factor: 3.312

Review 3.  Fluconazole pharmacokinetics and safety in premature infants.

Authors:  K Turner; P Manzoni; D K Benjamin; M Cohen-Wolkowiez; P B Smith; M M Laughon
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Fluconazole loading dose pharmacokinetics and safety in infants.

Authors:  Lauren Piper; P Brian Smith; Christoph P Hornik; Ira M Cheifetz; Jeffrey S Barrett; Ganesh Moorthy; William W Hope; Kelly C Wade; Michael Cohen-Wolkowiez; Daniel K Benjamin
Journal:  Pediatr Infect Dis J       Date:  2011-05       Impact factor: 2.129

5.  Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis.

Authors:  Yu Kyong Kim; Juyoung Lee; Jaeseong Oh; Su-Jin Rhee; Seung Han Shin; Seo Hyun Yoon; SeungHwan Lee; Han-Suk Kim; Kyung-Sang Yu
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

6.  Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants.

Authors:  Kelly C Wade; Daniel K Benjamin; David A Kaufman; Robert M Ward; Phillip B Smith; Bhuvana Jayaraman; Peter C Adamson; Marc R Gastonguay; Jeffrey S Barrett
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

7.  Association of fluconazole pharmacodynamics with mortality in patients with candidemia.

Authors:  John W Baddley; Mukesh Patel; Sujata M Bhavnani; Stephen A Moser; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

8.  Abdominal candidiasis is a hidden reservoir of echinocandin resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

9.  Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.

Authors:  S Leroux; E Jacqz-Aigrain; V Elie; F Legrand; C Barin-Le Guellec; B Aurich; V Biran; B Dusang; S Goudjil; S Coopman; R Garcia Sanchez; W Zhao; P Manzoni
Journal:  Br J Clin Pharmacol       Date:  2018-06-21       Impact factor: 4.335

10.  First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.

Authors:  Wei Zhao; Chantal Le Guellec; Daniel K Benjamin; William W Hope; Thomas Bourgeois; Kevin M Watt; Johannes N van den Anker; Boris Matrot; Harri Saxen; Kalle Hoppu; Paolo Manzoni; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.